Latest News and Press Releases

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Insomnia - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report...

Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée d’un produit brut de 116 millions d’euros dans le...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate...

Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's...

Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a....

Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025" report has been added to ...

Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...

Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's...

Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium.